Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) today announced that Company management will participate in the Jefferies Global Healthcare Conference, taking place June 5-6, 2024, in New York. Amit...
Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) today announced the expansion of the Companys leadership team with the addition of industry veteran Michael Hanley as chief operating officer (COO). Mr...
Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) today reported financial results for the first quarter ended March 31, 2024, and highlighted recent corporate progress. Our teams commitment to developing...
Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) today announced upcoming data presentations that highlight the companys precision psychiatry pipeline and biomarker-based analyses at the Society of...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) today reported financial results for the full year ended December 31, 2023, and highlighted recent corporate progress. 2024 is shaping up to be a...
Alto Neurosciences (NYSE:ANRO Get Free Report) quiet period is set to end on Wednesday, March 13th. Alto Neuroscience had issued 8,040,000 shares in its IPO on February 2nd. The total...
Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) today announced the appointment of Maha Radhakrishnan, M.D. to the companys board of directors. Dr. Radhakrishnan is an accomplished industry executive...
Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) today announced that company management will participate in the following upcoming investor conferences: Jefferies Biotech on the Bay Summit, March...